Waters Corporation stocks have been trading up by 12.38 percent amid strong demand outlook and favorable analyst sentiment.
Click Here for a Millionaire's POV on Trading WAT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- The U.S. FDA cleared Waters’ Onclarity HPV At-Home Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping, opening a reimbursed at-home screening channel across major U.S. payors.
- Shares of WAT jumped about 4.5% after the HPV clearance, signaling traders are already pricing in new revenue and strategic relevance from the at-home testing push.
- Evercore ISI upgraded Waters (WAT) to Outperform with a $350 target, pointing to achievable Q1 numbers and a stronger second half that could power a comeback in the stock.
- Several major firms trimmed price targets on Waters but largely kept positive or neutral ratings, while the Street’s average target in the high-$380s to high-$390s still implies upside from current levels.
- Waters launched the omniDAWN extended-range MALS detector for high-growth biologics and advanced materials workflows, with global rollout targeted for summer 2026.
Live Update At 14:03:09 EDT: On Tuesday, May 05, 2026 Waters Corporation stock [NYSE: WAT] is trending up by 12.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Waters Corporation, trading as WAT, has been grinding higher in recent sessions. From 2026/04/10 around $320 to 2026/05/05 near $339.26, WAT has added almost $20, with a sharp pop from $301.88 on 2026/05/04 to the mid-$340s intraday on 2026/05/05. That kind of gap-and-run tells traders a fresh catalyst is in play and dip-buyers are active.
Intraday action on 2026/05/05 shows WAT holding the $338–$341 zone for hours. Range is tight, volume is likely elevated, and every push into the mid-$340s is getting sold but not collapsing. That’s classic consolidation after a news-driven spike.
Fundamentally, Waters throws off rich margins. Gross margin sits around 78%, with EBIT margin above 26% and profit margin above 20%. For a tools and diagnostics name, that is elite. The flip side is valuation: a P/E near 28.5 and price-to-sales around 9.5 mean WAT is not cheap. Traders are paying up for quality, consistency, and a solid niche.
More Breaking News
- KOPN Stock Draws Bulls On AI Data Center And Drone Deals
- Celcuity CELC Soars On Strong Phase 3 Cancer Data
- ADT Stock Holds Range As Data Breach Raises Questions
- STRL Stock Soars After Massive Earnings Beat And Raised Outlook
Leverage looks controlled. Total debt-to-equity around 0.58, interest coverage over 14x, and a current ratio of 1.7 all suggest Waters can fund growth without stressing the balance sheet. Combined with strong returns on equity north of 40%, WAT screens as a high-quality, earnings-driven story where sentiment swings — not solvency worries — drive the chart.
Why Traders Are Watching WAT Now
The main reason WAT is front and center for active traders is the U.S. FDA green light on its Onclarity HPV At-Home Self-Collection Kit, plus approval of the BD Onclarity HPV Assay with extended genotyping. This is not a minor line extension. It opens a nationwide, prescription-based at-home cervical cancer screening channel that will be reimbursed by private insurers, Medicaid, and Medicare and rolled out over the coming months.
That combination — at-home, reimbursed, and cancer screening — is exactly the kind of story that gets growth traders leaning long. The immediate 4.5% jump in WAT after the FDA headlines shows the market sees real incremental revenue potential. For short-term players, that move confirms the catalyst has teeth.
Layer on top the analyst backdrop. Evercore ISI upgraded Waters to Outperform with a $350 target, highlighting confidence that Q1 numbers are in reach and calling for a stronger second half of 2026. For WAT, that’s a clear “earnings risk looks manageable” message, and it supports the idea of an upside inflection later in the year.
Yes, other shops — Leerink Partners, Wolfe Research, UBS, TD Cowen — have trimmed price targets. But they mostly stuck with Outperform or Neutral/Hold ratings. Street averages in roughly the $387–$394 area still sit well above the recent $330s. That tells traders the Street sees upside, just with expectations dialed back.
Meanwhile, Waters is not standing still on the product front. The launch of the omniDAWN extended-range multi-angle light scattering detector targets booming areas like biologics, viral vectors, lipid nanoparticles, and advanced materials. With global availability planned for summer 2026, omniDAWN gives WAT a medium-term growth lever that slots in nicely beside the nearer-term HPV catalyst.
Add in the scheduled Q1 2026 earnings call on 2026/05/05 and a near-term EPS event before the open, and WAT has both news flow and technical momentum — exactly what active traders want.
Conclusion
For traders, WAT now sits at the crossroads of strong fundamentals, new catalysts, and real event risk. The FDA clearance of the Onclarity HPV At-Home Self-Collection Kit and approval of the BD Onclarity HPV Assay give Waters Corporation a fresh, reimbursed channel in a critical screening market. The stock’s 4.5% surge on the news, plus follow-through into the high-$330s, confirms the tape respects that story.
At the same time, WAT carries a premium valuation, and multiple firms have nudged price targets lower even while keeping constructive ratings. That mix usually means one thing for active traders: expect volatility around earnings. A clean beat and bullish commentary on HPV rollout and omniDAWN adoption could push WAT toward the Street’s higher targets. A miss or cautious tone could send the stock back to test the low-$300s support band visible in the recent chart.
Waters’ Q1 call on 2026/05/05 is the next big mile marker. That’s where management can frame how fast at-home HPV testing and new tools like omniDAWN might translate into revenue and margin expansion.
As Tim Sykes likes to say, “Patterns repeat because human nature doesn’t change — study the catalysts, study the charts, and always, always manage your risk.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. For WAT, the catalysts are clear and the pattern is forming. It’s up to each trader to decide how to trade it — with tight risk, a clear plan, and zero emotion.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.